Bench to bedside: Current advances in regenerative medicine

Clarke, Gabriella; Harley, Peter; Hubber, Ella-Louise; Manea, Teodora; Manuelli, Luigi; Read, Emily; Watt, Fiona M.

doi:10.1016/j.ceb.2018.05.006

Cited by 14 publications

(4 citation statements)

References 57 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stem cell and regenerative medicine research is making steady progress from the bench to the bedside [1]. Along with this growth and progress, specific challenges have emerged.…”

mentioning

confidence: 99%

Rapid Change of a Cohort of 570 Unproven Stem Cell Clinics in the USA Over 3 Years

Knoepfler

2019

Regen. Med.

View full text Add to dashboard Cite

Aim: The industry of unproven stem cell clinics has rapidly mushroomed throughout the USA, posing risks to patients and the research field. In this study, the aim was to better define how this industry changes. Methods: I analyzed a large cohort of US stem cell clinic firms and their distinct clinic locations as defined in 2015–2016 for their status now in 2019. Results: About a quarter of the firms no longer marketed stem cells. Some lacked active websites, while others dropped stem cell services. Even so, the total number of clinics in this group increased because some firms greatly expanded their clinic numbers. Conclusion: Overall, the unproven clinic industry is a moving target requiring ongoing study and regulatory oversight.

show abstract

“…Stem cell and regenerative medicine research is making steady progress from the bench to the bedside [1]. Along with this growth and progress, specific challenges have emerged.…”

mentioning

confidence: 99%

Rapid Change of a Cohort of 570 Unproven Stem Cell Clinics in the USA Over 3 Years

Knoepfler

2019

Regen. Med.

View full text Add to dashboard Cite

show abstract

“…What is more, although stem cell delivery with DAF‐G might show a better result in the repair of AF defect, cell‐based therapy is not a very convenient and highly operable way to induce regeneration. An alternative and attractive strategy for regenerative medicine is to target endogenous repair mechanisms in resident cell populations to induce in situ regeneration (Clarke et al, ). The outcomes suggested that the decellularized matrix provided hospitable cell niches and the biochemical cues for resident cells' migration and growth (D'Este, Eglin, & Alini, ).…”

Section: Discussionmentioning

confidence: 99%

Genipin‐crosslinked decellularized annulus fibrosus hydrogels induces tissue‐specific differentiation of bone mesenchymal stem cells and intervertebral disc regeneration

Peng

Huang

et al. 2020

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Biomaterial‐based therapy that can restore annulus fibrosus (AF) function in early stage and promote endogenous repair of AF tissues is a promising approach for AF tissue repair. In this study, we established a genipin‐crosslinked decellularized AF hydrogels (g‐DAF‐G) that are injectable and could manifest better in situ formability than noncrosslinked decellularized AF hydrogel, while preserving the capacity of directing differentiation of human bone mesenchymal stem cells (hBMSCs) towards AF cells. Hematoxylin and eosin staining, 4',6‐diamidino‐2‐phenylindole staining, and so forth showed that the majority of cellular components were removed, whereas extracellular matrix and microstructure were largely preserved. The storage modulus increased from 465.5 ± 9.4 Pa to 3.29 ± 0.24 MPa after 0.02% genipin crosslinking of decellularized AF hydrogels (DAF‐G) to form g‐DAF‐G. AF‐specific genes (COL1A1, COL5A1, TNMD, IBSP, FBLN1) were significantly higher in DAF‐G and g‐DAF‐G groups than that in control group after 21 days of culturing. g‐DAF‐G significantly restored nucleus pulposus water content and preserved intervertebral structure in vivo. Summarily, we produced a novel AF regeneration biomaterial, g‐DAF‐G, which exhibited well biocompatibility, great bioactivity, and much higher mechanical strength than DAF‐G. This study will provide an easy and fast therapeutic alternative to repair AF injuries or tears.

show abstract

“…For example, ruptures require in most cases a surgical intervention, while other conditions may benefit from conservative therapies in order to control symptoms and possibly halt the degenerative process [28, 58]. In the scenario of non‐surgical approaches, regenerative medicine aims to promote and sustain tissue repair by exploitation of the self‐healing ability of the body [6, 25]. Regenerative medicine comprises a number of approaches, including the application of orthobiologics, i.e.…”

Section: Introductionmentioning

confidence: 99%

The effects of orthobiologics in the treatment of tendon pathologies: a systematic review of preclinical evidence

2022

View full text Add to dashboard Cite

Purpose The aim of this systematic review is to explore the current available knowledge about tendon disorders and orthobiologics derived by preclinical experiments to evaluate their role and efficacy in the different stages and conditions related to the tendon healing processes. Methods The systematic review was performed according to the PRISMA guidelines. Different electronic databases (MEDLINE, Web of Science, EMBASE) were searched for studies investigating orthobiologics (PRP and cell-based products from adipose tissue or bone marrow) in animal models or veterinary clinical trials for tendon pathologies (complete/partial tendon ruptures, rotator cuff tears, tendinopathy, enthesis-related injuries). Data regarding the specific product used, the treatment site/pathology, the host and the model were collected. The results were classified into the following categories: histological, biomechanical, molecular and imaging. Results A large pool of preclinical studies on tendon disorders have been found on platelet-rich plasma (PRP), while data about stromal vascular fraction (SVF) and bone marrow concentrate (BMAC) are still limited and frequently focused on expanded cells, rather than orthobiologics prepared at the point of care. The effect of PRP is related to an acceleration of the healing process, without improvements in the final structure and properties of repaired tendon. Cell-based products have been reported to produce more durable results, but the level of evidence is currently insufficient to draw clear indications. Conclusions The preclinical results about orthobiologics applications to tendon pathologies would support the rationale of their clinical use and encourage the performance of clinical trials aimed to confirm these data in human subjects.

show abstract

Bench to bedside: Current advances in regenerative medicine

Cited by 14 publications

References 57 publications

Rapid Change of a Cohort of 570 Unproven Stem Cell Clinics in the USA Over 3 Years

Rapid Change of a Cohort of 570 Unproven Stem Cell Clinics in the USA Over 3 Years

Genipin‐crosslinked decellularized annulus fibrosus hydrogels induces tissue‐specific differentiation of bone mesenchymal stem cells and intervertebral disc regeneration

The effects of orthobiologics in the treatment of tendon pathologies: a systematic review of preclinical evidence

Contact Info

Product

Resources

About